J
Jeffrey M. Schkeryantz
Researcher at Eli Lilly and Company
Publications - 56
Citations - 1533
Jeffrey M. Schkeryantz is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: GABAA receptor & Metabotropic receptor. The author has an hindex of 22, co-authored 55 publications receiving 1409 citations. Previous affiliations of Jeffrey M. Schkeryantz include University of Michigan & Kettering University.
Papers
More filters
Patent
Peroxisome proliferator activated receptor modulators
Scott Eugene Conner,James Allen Knobelsdorf,Nathan Bryan Mantlo,Jeffrey M. Schkeryantz,Shen Quanrong,Warshawsky Alan M,Guoxin Zhu +6 more
TL;DR: In this article, a peroxisome proliferator activated receptor (PPAR) was used to treat or prevent disorders mediated by a PPAR such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
Journal ArticleDOI
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes
Matthew J. Fell,Jeffrey M. Witkin,Julie F. Falcone,Jason Katner,Kenneth W. Perry,John Hart,Linda M. Rorick-Kehn,Carl D Overshiner,Kurt Rasmussen,Stephen F. Chaney,Mark J. Benvenga,Xia Li,Deanna L Marlow,Linda K. Thompson,Susan K Luecke,Keith A. Wafford,Wesley F. Seidel,Dale M. Edgar,Anne T. Quets,Christian C. Felder,Xushan Wang,Beverly A. Heinz,Alexander Nikolayev,Ming-Shang Kuo,Daniel Ray Mayhugh,Albert Khilevich,Deyi Zhang,Phillip J Ebert,James E Eckstein,Bradley L. Ackermann,Steven P. Swanson,John T. Catlow,Robert A. Dean,Kimberley Jackson,Sitra Tauscher-Wisniewski,Gerard J. Marek,Jeffrey M. Schkeryantz,Kjell Svensson +37 more
TL;DR: The results indicate that the novel mGlu2-positive allosteric modulator THIIC has robust activity in models used to predict anxiolytic/antidepressant efficacy, substantiating, at least with this molecule, differentiation in the biological impact of mGLU2 potentiation versus mGlam2/3 orthosteric agonism.
Journal ArticleDOI
Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis
Philip J. Hajduk,Jürgen Dinges,Jeffrey M. Schkeryantz,David A. Janowick,Kaminski Michele A,Michael D. Tufano,David J. Augeri,Andrew M. Petros,Vicki L. Nienaber,Ping Zhong,Rachel Hammond,Michael L. Coen,Bruce A. Beutel,Leonard Katz,Stephen W. Fesik +14 more
TL;DR: NMR and X-ray structures of enzyme/inhibitor complexes reveal that the inhibitors bind to the S-adenosylmethionine binding site on the Erm protein, representing novel methyltransferase inhibitors that serve as new leads for the reversal of Erm-mediated MLS antibiotic resistance.
Patent
Pharmaceutically active 4-substituted pyrimidine derivatives
Ambler Samantha Jayne,Stephen Richard Baker,Barry Peter Clark,Coleman Darrell Stephen,Foglesong Robert James,John Goldsworthy,Hong Jian Eric,Gunnar Erik Junior Jagdmann,Kirk W. Johnson,Ann E. Kingston,Owton William Martin,Jeffrey M. Schkeryantz,Darryle Darwin Schoepp,Michael S. VanNieuwenhze,Mohammad Zia-Ebrahimi +14 more
TL;DR: In this article, the use of 4-substituted pyrimidine derivatives as mGluR1 antagonists was discussed. But the main focus of the present paper was on the synthesis of a process for the preparation of 4 -substantially modified pyridine derivatives.
Journal ArticleDOI
Intramolecular Schmidt reactions of azides with carbocations: synthesis of bridged-bicyclic and fused-bicyclic tertiary amines
William H. Pearson,Rajesh Walavalkar,Jeffrey M. Schkeryantz,Wen Kui Fang,James D. Blickensdorf +4 more
TL;DR: In this paper, the Schmidt reaction was used to generate bridged-or fused-bicyclic a-amino carbocations or iminium ions, depending on the geometry about the C(+)-N bond.